ZD 0473

In the 30 years since the introduction of cisplatin into the clinic, laboratory studies have provided considerable information as… Expand

Following the introduction of cisplatin and the demonstration of its importance in the treatment of testicular and ovarian cancer… Expand

We present the method of theoretical calculations of the Raman intensities and the simulated Raman spectra of platinum(II… Expand

BACKGROUND AMD473 (previously ZD0473) is a new-generation platinum compound with activity against a wide range of human tumour… Expand

The use of chemotherapy is considered standard therapy in patients with locally advanced non-small-cell lung cancer that cannot… Expand

ZD0473 is a new generation hindered platinum agent currently undergoing worldwide Phase II clinical studies. The in vitro… Expand

A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural… Expand

The discovery of cisplatin more than two decades ago was the most important therapeutic advance in the treatment of ovarian… Expand

Wild-type p53 is frequently mutated in late-stage ovarian cancer and has been proposed as a determinant of cisplatin… Expand

Acquired drug resistance to the sterically hindered platinum drug ZD0473 (formerly known as JM473 and AMD473) and currently being… Expand